Table 1.
Patient characteristics at baseline.
| Characteristics | n = 15 | % |
|---|---|---|
| Age at diagnosis | ||
| Median (years) | 48 | |
| Range (years) | 26–69 | |
| KI-67 proliferation rate | ||
| Median (%) | 75 | |
| Range (%) | 10–90 | |
| Histology | ||
| Ductal | 14 | 93 |
| Medullary | 1 | 7 |
| Grade | ||
| G2 | 4 | 27 |
| G3 | 11 | 73 |
| Tumor size | ||
| T1 | 7 | 47 |
| T2 | 7 | 47 |
| T3 | 0 | 0 |
| T4 | 1 | 7 |
| Nodal status | ||
| cN0 | 12 | 80 |
| ≥pN1 | 3 | 20 |
| BRCA1/2 germline mutation | ||
| yes | 9 | 60 |
| no | 5 | 33 |
| unknown | 1 | 7 |
| Neoadjuvant systemic therapy |
||
| yes | 13 | 87 |
| EC * + Paclitacel/Carboplatin | 9 | 60 |
| AC * + Paclitacel/Carboplatin | 2 | 13 |
| Docetaxel + Carboplatin | 2 | 13 |
| no | 2 | 13 |
| Pathologic complete response after NACT (n = 13) | ||
| yes | 12 | 92 |
| no | 1 | 8 |
* EC: epirubicin + cyclophosphamide; AC: doxorubicin + cyclophosphamide; NACT: neoadjuvant chemotherapy.